- Condition: Multiple Myeloma
Interventions: Drug: Placebo; Drug: Dexamethasone; Drug: Bortezomib; Biological: Tabalumab
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Not yet recruiting - verified May 2012 - Condition: Cataract
Interventions: Drug: 40 mg/mL Dexamethasone phosphate ophthalmic solution; Drug: 100 mM sodium citrate buffer solution
Sponsors: Eyegate Pharmaceuticals, Inc.; Eyegate Pharmaceuticals, Inc.
Not yet recruiting - verified May 2012 - Conditions: Cancer; Stress
Interventions: Behavioral: Spanish-Language Self-Administered Training Plus Usual Care (SL-SAT); Behavioral: Usual Care Only
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; H. Lee Moffitt Cancer Center and Research Institute; American Cancer Society; University of Miami
Recruiting - verified May 2012 - Conditions: Anterior Cruciate Ligament Reconstruction; Regional Anesthesia, Saphenous Nerve Block
Interventions: Drug: Bupivacaine Only; Drug: Bupivacaine with 2 ml of Dexamethasone; Drug: Bupivacaine with 4 mg of Dexamethasone
Sponsors: Hospital for Special Surgery, New York; Hospital for Special Surgery, New York
Not yet recruiting - verified April 2012 - Condition: Alcoholism
Interventions: Drug: Ondansetron + Brief Behavioral Enhancement Treatment; Drug: Placebo + Brief Behavioral Enhancement Treatment
Sponsors: University of Virginia; Bankole Johnson; National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Not yet recruiting - verified May 2012 - Condition: Retinal Vein Occlusion
Intervention: Drug: Dexamethasone with rescue ranibizumab
Sponsors: Wills Eye; Wills Eye
Not yet recruiting - verified April 2012 - Condition: Chronic Obstructive Pulmonary Disease
Interventions: Drug: aprepitant; Drug: placebo
Sponsors: Dartmouth-Hitchcock Medical Center; Dartmouth-Hitchcock Medical Center
Recruiting - verified April 2012 - Conditions: Congenital Heart Disease; Disorder of Fetus or Newborn
Interventions: Drug: Methylprednisolone; Drug: Placebo
Sponsors: Medical University of South Carolina; Medical University of South Carolina; National Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health (NIH)
Not yet recruiting - verified April 2012 - Condition: Multiple Myeloma
Interventions: Drug: Carfilzomib; Drug: Lenalidomide; Drug: Dexamethasone
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified March 2012 - Condition: Healthy
Interventions: Drug: Ondansetron; Drug: Ondansetron + Hylenex; Drug: Zofran ODT; Drug: Ondansetron solution
Sponsors: Halozyme Therapeutics; Halozyme Therapeutics
Recruiting - verified April 2012 - Conditions: Diabetic Macular Edema.; Non-proliferative Diabetic Retinopathy; Proliferative Diabetic Retinopathy
Interventions: Drug: dexamethasone intravitreal implant; Drug: intravitreal bevacizumab
Sponsors: Retina Macula Institute; Retina Macula Institute; Allergan
Recruiting - verified April 2012 - Conditions: Feeding Disorder; Nutrition Disorder; Infant,Premature
Interventions: Drug: Metclopramide; Drug: Erythromycin; Drug: placebo
Sponsors: East Tennessee State University; East Tennessee State University
Recruiting - verified March 2012 - Conditions: Orthostatic Hypotension; Hemodynamic Instability; Fever; Hypothermia
Interventions: Drug: Hydrocortisone; Drug: Hydrocortisone
Sponsors: Cedars-Sinai Medical Center; Cedars-Sinai Medical Center
Recruiting - verified March 2012 - Condition: Nausea and Vomiting
Interventions: Drug: lorazepam; Drug: diphenhydramine hydrochloride; Drug: haloperidol; Other: placebo
Sponsors: Virginia Commonwealth University; Virginia Commonwealth University; National Cancer Institute (NCI)
Recruiting - verified March 2012 - Conditions: Blood Donor; Leukocyte Transfusion; Granulocyte Colony-Stimulation Factor; Blood Component Removal
Interventions: Drug: Filgrastim (G-CSF); Drug: Dexamethasone
Sponsors: National Institutes of Health Clinical Center (CC); National Institutes of Health Clinical Center (CC)
Recruiting - verified February 2012 - Condition: Multiple Myeloma
Interventions: Drug: DPACE (Dexamethasone, Cisplatin, Adriamycin, Cyclophosphamide, Etoposide); Procedure: Transplant 1 (Velcade, Thalidomide, Dexamethasone, Melphalan); Procedure: Transplant 2 (Velcade, Gemcitabine, Carmustine, Dexamethasone, Melphalan); Drug: Consolidation VDT-PACE (Velcade, Dexamethasone, Thalidomide, Cisplatin, Adriamycin, Cyclophosphamide, Etoposide); Drug: Maintenance Year 1 (Velcade, Thalidomide, Dexamethasone OR Velcade, Revlimid, Dexamethasone OR Velcade, Cyclophosphamide, Dexamethasone in 28 day cycles x 12); Drug: Maintenance Year 2 (Revlimid and Dexamethasone in 28 day cycles x 12)
Sponsors: University of Iowa; University of Iowa; National Cancer Institute (NCI)
Not yet recruiting - verified March 2012 - Condition: Postoperative Complications
Interventions: Drug: Placebo-saline; Drug: Dexamethasone 4 mg; Drug: Dexamethasone 8 mg
Sponsors: NorthShore University HealthSystem Research Institute; NorthShore University HealthSystem Research Institute
Recruiting - verified March 2012 - Condition: AL Amyloidosis
Interventions: Drug: Pomalidomide; Drug: Dexamthasone
Sponsors: Boston Medical Center; Boston Medical Center; Celgene Corporation
Not yet recruiting - verified February 2012 - Condition: Cancer of the Cervix
Interventions: Drug: Granisetron; Drug: Ondansetron; Behavioral: Questionnaires; Behavioral: Study Drug Diary
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Sancuso
Recruiting - verified March 2012 - Conditions: Shoulder Pain; Injury of Shoulder Region; Disorder of Shoulder; Disorder of Rotator Cuff; Disorder of Tendon of Biceps
Interventions: Drug: Dexamethasone; Drug: Bupivacaine
Sponsors: Lifespan; Lifespan; Tufts Medical Center; United States Naval Medical Center, Portsmouth
Not yet recruiting - verified March 2012 - Condition: Multiple Myeloma
Interventions: Drug: Pomalidomide; Drug: Pegylated Liposomal Doxorubicin (PLD); Drug: Dexamethasone
Sponsors: Oncotherapeutics; Oncotherapeutics; Celgene Corporation
Recruiting - verified February 2012 - Condition: Postoperative Pain.
Interventions: Drug: Subpleural pain catheter with infusion of 0.125% bupivacaine; Drug: Standard acute pain management
Sponsors: Inova Health Care Services; Inova Health Care Services
Not yet recruiting - verified February 2012 - Condition: Multiple Myeloma
Interventions: Drug: carfilzomib; Drug: Dexamethasone; Drug: Clarithromycin; Drug: Lenalidomide; Drug: Dexamethasone; Drug: Lenalidomide
Sponsors: Weill Medical College of Cornell University; Weill Medical College of Cornell University; Onyx Therapeutics, Inc.
Not yet recruiting - verified March 2012 - Conditions: Opioid Withdrawal; Physical Dependence
Intervention: Drug: Ondansetron
Sponsors: Stanford University; Stanford University; National Institute on Drug Abuse (NIDA)
Recruiting - verified March 2012 - Condition: Myeloma
Interventions: Drug: Lenalidomide; Drug: Bortezomib; Drug: Siltuximab; Drug: Dexamethasone; Behavioral: Questionnaires
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Janssen Services, LLC
Recruiting - verified May 2012 - Condition: Healthy
Interventions: Drug: Placebo; Drug: Meclizine; Drug: Meclizine
Sponsors: Duke University; Duke University; Wallace Foundation
Recruiting - verified February 2012 - Conditions: Cholangiocarcinoma; Liver Neoplasms
Interventions: Drug: floxuridine, dexamethasone; Drug: floxuridine, dexamethasone, gemcitabine hydrochloride; Drug: floxuridine, dexamethasone, gemcitabine hydrochloride, oxaliplatin
Sponsors: Washington University School of Medicine; Washington University School of Medicine
Recruiting - verified May 2012 - Conditions: Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma
Interventions: Drug: dalteparin; Drug: lenalidomide; Drug: dexamethasone; Other: laboratory biomarker analysis
Sponsors: USC/Norris Comprehensive Cancer Center; USC/Norris Comprehensive Cancer Center; National Cancer Institute (NCI); Celgene Corporation
Recruiting - verified January 2012 - Conditions: Pain; Total Knee Arthroplasty
Interventions: Drug: Dexamethasone; Drug: Ropivacaine
Sponsors: University of New Mexico; University of New Mexico
Not yet recruiting - verified April 2012 - Condition: Opioid Dependence
Interventions: Drug: Aprepitant; Drug: Placebo pill
Sponsors: New York University; New York University; National Institute on Drug Abuse (NIDA)
Recruiting - verified February 2012 - Condition: Multiple Myeloma
Interventions: Drug: ACE-011; Drug: Lenalidomide; Drug: Dexamethasone
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital
Recruiting - verified May 2012 - Condition: Nausea and Vomiting Post-foregut Surgery
Intervention: Device: Reletex
Sponsors: Ohio State University; Kyle A Perry
Recruiting - verified January 2012 - Condition: Anterior Uveitis
Interventions: Drug: 40 mg/mL Dexamethasone phosphate ophthalmic solution; Drug: Prednisolone Acetate (1%) Eyedrops; Drug: 100 mM sodium citrate buffer solution; Drug: Placebo Eyedrops
Sponsors: Eyegate Pharmaceuticals, Inc.; Eyegate Pharmaceuticals, Inc.
Recruiting - verified May 2012 - Condition: Postoperative Nausea and Vomiting
Interventions: Drug: Ondansetron; Drug: Vestipitant
Sponsors: Octagon Research Solutions, Inc.; Octagon Research Solutions, Inc.
Recruiting - verified May 2012 - Condition: Cocaine Dependence
Interventions: Drug: Ketamine; Drug: Lorazepam (control)
Sponsors: New York State Psychiatric Institute; New York State Psychiatric Institute; National Institute on Drug Abuse (NIDA)
Recruiting - verified April 2012 - Condition: Agitation
Interventions: Drug: Haloperidol; Drug: Midazolam
Sponsors: Catholic Health East; Catholic Health East
Recruiting - verified December 2011 - Condition: Multiple Myeloma
Intervention: Drug: Vorinostat, Lenalinomide and Dexamethasone
Sponsors: Hackensack University Medical Center; Hackensack University Medical Center; Merck Sharp & Dohme Corp., Inc.
Recruiting - verified December 2011 - Condition: Chemotherapy-induced Nausea and Vomiting
Interventions: Drug: Rolapitant; Drug: Granisetron; Drug: Dexamethasone
Sponsors: Tesaro, Inc.; Tesaro, Inc.; Covance; Pharm Olam Pharmaceuticals Ltd.; Parexel; Biomedical Systems Corporation; XenoBiotic Laboratories
Recruiting - verified May 2012 - Conditions: Gastrointestinal Cancer; Nausea Post Chemotherapy
Intervention: Drug: fosaprepitant dimeglumine
Sponsors: Barbara Ann Karmanos Cancer Institute; Barbara Ann Karmanos Cancer Institute; National Cancer Institute (NCI)
Not yet recruiting - verified January 2012 - Condition: Chemotherapy-induced Nausea and Vomiting
Interventions: Drug: Rolapitant; Drug: Granisetron; Drug: Dexamethasone
Sponsors: Tesaro, Inc.; Tesaro, Inc.; Covance; Pharm Olam Pharmaceuticals Ltd.; Parexel; Biomedical Systems Corporation
Recruiting - verified May 2012 - Condition: Multiple Myeloma
Interventions: Drug: Pomalidomide; Drug: Bortezomib; Drug: Dexamethasone
Sponsors: Celgene Corporation; Celgene Corporation; Multiple Myeloma Research Consortium
Recruiting - verified April 2012 - Condition: Chemotherapy-induced Nausea and Vomiting
Interventions: Drug: Rolapitant; Drug: Granisetron; Drug: dexamethasone
Sponsors: Tesaro, Inc.; Tesaro, Inc.; Pharm Olam Pharmaceuticals Ltd.; Parexel; Covance; Biomedical Systems Corporation; XenoBiotic Laboratories
Recruiting - verified May 2012 - Conditions: Chronic Lymphocytic Leukemia (CLL); Small Lymphocytic Lymphoma (SLL)
Interventions: Drug: High Dose Methylprednisolone; Drug: Ofatumumab; Drug: Lenalidomide; Drug: Sargramostim
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; H. Lee Moffitt Cancer Center and Research Institute; GlaxoSmithKline; Celgene Corporation
Recruiting - verified January 2012 - Conditions: Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
Interventions: Drug: High Dose Methylprednisolone; Drug: Ofatumumab; Drug: Lenalidomide; Drug: Sargramostim
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; H. Lee Moffitt Cancer Center and Research Institute; GlaxoSmithKline; Celgene Corporation
Recruiting - verified January 2012 - Conditions: Sarcoma; Chemotherapy-induced Nausea and Vomiting; Effects of Chemotherapy; Adverse Effects of Medical Drugs
Interventions: Drug: Fosaprepitant; Drug: Dexamethasone; Drug: 5HT3 receptor antagonist; Drug: Ifosfamide-based chemotherapy (AI); Drug: Doxorubicin; Drug: Mesna; Drug: Ifosfamide; Drug: Vincristine
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Merck
Not yet recruiting - verified March 2012 - Condition: Healthy
Interventions: Drug: Olanzapine; Drug: Placebo
Sponsors: State University of New York at Buffalo; State University of New York at Buffalo
Recruiting - verified December 2011 - Condition: Macular Edema
Interventions: Drug: dexamethasone Intravitreal Implant; Drug: ranibizumab
Sponsors: Allergan; Allergan
Recruiting - verified May 2012 - Conditions: Contiguous Stage II Mantle Cell Lymphoma; Noncontiguous Stage II Mantle Cell Lymphoma; Stage I Mantle Cell Lymphoma; Stage III Mantle Cell Lymphoma; Stage IV Mantle Cell Lymphoma
Interventions: Biological: ofatumumab; Drug: cyclophosphamide; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: vincristine sulfate; Drug: cytarabine; Procedure: autologous hematopoietic stem cell transplantation; Drug: methotrexate
Sponsors: Roswell Park Cancer Institute; Roswell Park Cancer Institute; National Comprehensive Cancer Network
Recruiting - verified April 2012 - Condition: Duration of Interscalene Block
Interventions: Other: ropivacaine plus dexamethasone anesthetic; Other: ropivacaine plus saline plus dexamethasone anesthetic
Sponsors: The Cleveland Clinic; The Cleveland Clinic
Recruiting - verified December 2011 - Conditions: Pre-diabetes; Impaired Fasting Glucose; Impaired Glucose Tolerance
Intervention: Drug: Dexamethasone
Sponsors: University of Vermont; University of Vermont; Merck
Not yet recruiting - verified December 2011 - Condition: Multiple Myeloma
Interventions: Drug: Ganetespib Dexamethasone; Drug: Bortezomib; Drug: Dexamethasone
Sponsors: Emory University; Emory University; Multiple Myeloma Research Consortium
Recruiting - verified March 2012 - Conditions: Acute Lymphoblastic Leukemia; Precursor B-Cell Lymphoblastic Leukemia; Precursor T-Cell Lymphoblastic Leukemia
Interventions: Drug: Decitabine; Drug: Vorinostat; Drug: Vincristine; Drug: Dexamethasone; Drug: Mitoxantrone; Drug: Pegaspargase; Drug: Methotrexate
Sponsors: Therapeutic Advances in Childhood Leukemia Consortium; Therapeutic Advances in Childhood Leukemia Consortium
Recruiting - verified March 2012 - Condition: Multiple Myeloma
Interventions: Drug: Bendamustine; Drug: Bortezomib; Drug: Lenalidomide; Drug: Dexamethasone
Sponsors: Loyola University; Loyola University
Recruiting - verified December 2011 - Condition: PTSD
Interventions: Drug: Dexamethasone; Drug: Dexamethasone
Sponsors: Emory University; Emory University; National Institute of Mental Health (NIMH)
Recruiting - verified November 2011 - Condition: Cataract
Interventions: Drug: Loteprednol etabonate; Drug: Prednisolones acetate
Sponsors: Bausch & Lomb, Inc.; Bausch & Lomb, Inc.
Not yet recruiting - verified November 2011 - Condition: Asthma
Interventions: Drug: Mometasone Furoate/Formoterol MDI 100/5 mcg; Drug: Mometasone Furoate/Formoterol MDI 200/5 mcg; Drug: Mometasone Furoate MDI 100 mcg; Drug: Mometasone Furoate MDI 200 mcg; Drug: Albuterol 90 mcg /salbutamol 100 mcg HFA MDI; Drug: Prednisone/prednisolone
Sponsors: Schering-Plough; Schering-Plough
Recruiting - verified April 2012 - Condition: Peripheral Arterial Disease
Intervention: Procedure: Administration of dexamethasone to SFA/popliteal adventitia
Sponsors: University of California, San Francisco; University of California, San Francisco
Recruiting - verified January 2012 - Conditions: PONV; Nausea
Interventions: Drug: Aprepitant; Drug: Ondansetron
Sponsors: Ohio State University; Sergio Bergese
Recruiting - verified November 2011 - Condition: Migraine
Interventions: Drug: Ketorolac; Drug: Placebo
Sponsors: Akron Children's Hospital; Akron Children's Hospital
Recruiting - verified February 2012 - Conditions: Macular Edema; Cystoid Macular Edema; Uveal Melanoma; Radiation Maculopathy; Radiation Retinopathy
Intervention: Drug: Ozurdex (Dexamethasone intravitreal implant )
Sponsors: Wills Eye; Arman Mashayekhi; Allergan
Not yet recruiting - verified November 2011 - Condition: Multiple Myeloma
Interventions: Biological: Elotuzumab; Drug: Bortezomib; Drug: Dexamethasone; Drug: Dexamethasone; Drug: Dexamethasone; Drug: Dexamethasone
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Abbott Biotherapeutics Corp.
Recruiting - verified February 2012 - Condition: Multiple Myeloma
Interventions: Drug: masitinib 6 mg/kg/day; Drug: placebo
Sponsors: AB Science; AB Science
Recruiting - verified November 2011 - Condition: Multiple Myeloma
Interventions: Drug: Carfilzomib; Drug: Pomalidomide; Drug: Dexamethasone
Sponsors: Academic Myeloma Consortium; Academic Myeloma Consortium; CORE Science Solutions; Onyx Pharmaceuticals; Celgene Corporation
Recruiting - verified February 2012 - Conditions: CLL; SLL
Interventions: Drug: Ofatumumab; Drug: High-Dose Methylprednisolone; Drug: Alemtuzumab
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute; National Comprehensive Cancer Network; GlaxoSmithKline
Recruiting - verified December 2011 - Condition: Lung Cancer
Interventions: Drug: DOTAP:Chol-fus1; Drug: Erlotinib; Drug: Dexamethasone; Drug: Diphenhydramine
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Convergen LifeSciences, Inc.
Not yet recruiting - verified March 2012 - Conditions: Nausea; Vomiting; Glioma
Interventions: Drug: Aprepitant and Ondansetron; Drug: Ondansetron
Sponsors: Duke University; Duke University; Merck
Not yet recruiting - verified March 2012 - Condition: Interscalene Blockade in Elective Arthroscopic Rotator Cuff Repair
Interventions: Drug: Ropivacaine; Drug: Dexamethasone; Drug: Dexamethasone; Drug: Normal saline; Drug: Normal saline
Sponsors: Mayo Clinic; Mayo Clinic
Recruiting - verified May 2012 - Condition: Postoperative Nausea and Vomiting
Interventions: Drug: general balanced anesthesia; Drug: TIVA NoNarc
Sponsors: Coastal Anesthesiology Consultants; Coastal Anesthesiology Consultants
Recruiting - verified November 2011 - Conditions: Retinal Vein Occlusion; Macular Edema
Interventions: Drug: Ozurdex; Drug: Ozurdex
Sponsors: Retina Macula Institute; Retina Macula Institute; Allergan
Recruiting - verified April 2012 - Condition: Cornea Transplant Recipients
Interventions: Drug: Prednisolone acetate; Drug: Fluorometholone
Sponsors: Price Vision Group; Price Vision Group
Recruiting - verified April 2012 - Condition: Smoking Cessation
Interventions: Drug: Meclizine; Drug: Nicotine patches
Sponsors: Duke University; Duke University; Philip Morris USA, Inc.
Recruiting - verified March 2012 - Condition: Scleroderma
Interventions: Procedure: Rituximab sandwich regiment followed by SCT; Procedure: cyclophosphamide regiment followed by SCT
Sponsors: Northwestern University; Richard Burt, MD
Recruiting - verified April 2012 - Condition: Waldenstrom's Macroglobulinemia
Interventions: Drug: Dexamethasone; Drug: Carfilzomib; Drug: Rituximab
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute; Onyx Pharmaceuticals
Recruiting - verified November 2011 - Condition: Myeloma
Interventions: Drug: Panobinostat; Drug: Bortezomib; Drug: Lenalidomide; Drug: Dexamethasone; Behavioral: Symptom Questionnaire
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Novartis
Not yet recruiting - verified March 2012 - Condition: Chemotherapy-Induced Nausea and Vomiting
Interventions: Drug: Palonosetron; Drug: Palonosetron; Drug: Ondansetron
Sponsors: Helsinn Healthcare SA; Helsinn Healthcare SA
Recruiting - verified May 2012 - Condition: Healthy Volunteer
Interventions: Drug: RO4917838; Drug: diazepam; Drug: Placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Conditions: Surgery; Pain
Interventions: Drug: .9 normal saline; Drug: 25 mg diphenhydramine IV; Drug: 50 mg diphenhydramine IV
Sponsors: Northwestern University; Northwestern University
Recruiting - verified February 2012 - Condition: Myeloma
Interventions: Drug: Pomalidomide; Drug: Dexamethasone; Drug: Cyclophosphamide
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; H. Lee Moffitt Cancer Center and Research Institute; Celgene Corporation
Recruiting - verified May 2012 - Condition: Psychotic Depression
Interventions: Drug: Olanzapine; Drug: Placebo
Sponsors: Weill Medical College of Cornell University; Weill Medical College of Cornell University; University of Toronto; University of Massachusetts, Worcester; University of Pittsburgh
Recruiting - verified March 2012 - Condition: Postoperative Vomiting and Nausea
Intervention: Device: Acupuncture Needle
Sponsors: Oregon Health and Science University; Oregon Health and Science University
Recruiting - verified August 2011 - Condition: Leukemia
Interventions: Drug: Cyclophosphamide; Drug: Mesna; Drug: Doxorubicin; Drug: Vincristine; Drug: Dexamethasone; Drug: Ponatinib; Drug: G-CSF (Filgrastim); Drug: Rituximab; Drug: Methotrexate; Drug: Cytarabine; Drug: Solu-medrol ( Methyl Prednisolone); Drug: Citrovorum (Leucovorin); Drug: Prednisone; Drug: Pegfilgrastim (Neulasta)
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Ariad Pharmaceuticals
Recruiting - verified May 2012 - Conditions: Obesity; Hyperandrogenemia; Polycystic Ovary Syndrome
Interventions: Drug: Metformin; Drug: Dexamethasone; Drug: Cosyntropin; Drug: r-hCG (Ovidrel)
Sponsors: University of Virginia; University of Virginia
Not yet recruiting - verified August 2011 - Conditions: Obesity; Hyperandrogenemia; Polycystic Ovary Syndrome
Interventions: Drug: Spironolactone; Drug: Dexamethasone; Drug: Cosyntropin; Drug: r-hCG (Ovidrel)
Sponsors: University of Virginia; University of Virginia
Not yet recruiting - verified August 2011 - Conditions: Hyperandrogenemia; Obesity; Polycystic Ovary Syndrome
Interventions: Drug: Hydrocortisone; Drug: dexamethasone; Drug: Cosyntropin; Drug: r-hCG (Ovidrel)
Sponsors: University of Virginia; University of Virginia
Not yet recruiting - verified August 2011 - Conditions: Hyperandrogenemia; Polycystic Ovary Syndrome; Obesity
Interventions: Drug: Dexamethasone; Drug: Cortrosyn
Sponsors: University of Virginia; University of Virginia; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); University of California, San Diego
Recruiting - verified August 2011 - Conditions: Hyperandrogenemia; Obesity; Polycystic Ovary Syndrome
Interventions: Drug: Leuprolide; Drug: Dexamethasone; Drug: recombinant human chorionic gonadotropin
Sponsors: University of Virginia; University of Virginia
Not yet recruiting - verified August 2011 - Conditions: Hyperandrogenemia; Obesity; Polycystic Ovary Syndrome
Interventions: Drug: Hydrocortisone; Drug: dexamethasone; Drug: Cosyntropin (ACTH)
Sponsors: University of Virginia; University of Virginia
Not yet recruiting - verified August 2011 - Conditions: Schizophrenia; Schizoaffective Disorder
Interventions: Behavioral: Visual Decision Aid and Shared Decision Making Model; Behavioral: Usual Care
Sponsors: VA Nebraska Western Iowa Health Care System; VA Nebraska Western Iowa Health Care System; New England MIRECC; Nebraska Educational Biomedical Research Association
Recruiting - verified August 2011 - Condition: Lymphoblastic Lymphoma
Interventions: Drug: prednisone, vincristine, daunorubicin, PEG-asparaginase, methotrexate, hydrocortisone, cytarabine (IT-MH)A treatment, cyclophosphamide, cytarabine, thioguanine; Drug: PEG- asparaginase, High-Dose Methotrexate (HD-MTX) and Mercaptopurine; Drug: Dexamethasone, Doxorubicin; Vincristine; Mercaptopurine; PEG- Asparaginase, Cyclophosphamide, and Cytarabine; Drug: dexamethasone, cytarabine, etoposide, pegaspargase, clofarabine, cyclophosphamide; Drug: Intrathecal chemotherapy
Sponsors: St. Jude Children's Research Hospital; St. Jude Children's Research Hospital; National University, Singapore
Recruiting - verified April 2012 - Conditions: Polycystic Ovary Syndrome; Obesity; Hyperandrogenism
Interventions: Drug: Dexamethasone; Drug: r-hCG (Ovidrel)
Sponsors: University of Virginia; University of Virginia; University of California, San Diego
Recruiting - verified August 2011 - Condition: Epilepsy
Intervention: Drug: Diazepam
Sponsors: Neuronex, Inc.; Neuronex, Inc.
Recruiting - verified November 2011 - Condition: Multiple Myeloma
Interventions: Drug: GSK2110183; Drug: Bortezomib; Drug: Dexamethasone
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified February 2012 - Condition: Lymphoma
Interventions: Biological: rituximab; Drug: bendamustine hydrochloride; Drug: cyclophosphamide; Drug: cytarabine; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: leucovorin calcium; Drug: methotrexate; Drug: vincristine sulfate
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Multiple Myeloma
Interventions: Drug: proteasome inhibitor MLN9708; Drug: dexamethasone
Sponsors: Mayo Clinic; Mayo Clinic; National Cancer Institute (NCI)
Recruiting - verified March 2012 - Condition: Leukemia
Interventions: Drug: ATRA; Drug: ATO; Drug: GO (Gemtuzumab ozogamicin); Drug: Methylprednisolone
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Pfizer
Recruiting - verified March 2012 - Condition: Blepharitis
Interventions: Drug: ISV-502; Drug: Azasite; Drug: Dexamethasone; Other: Vehicle
Sponsors: InSite Vision; InSite Vision
Recruiting - verified April 2012 - Condition: Multiple Myeloma
Interventions: Drug: Carfilzomib; Drug: Lenalidomide; Drug: Dexamethasone
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI); Celgene Corporation; Onyx Therapeutics, Inc.
Recruiting - verified July 2011 - Conditions: Leukemia; Lymphoma
Interventions: Drug: dexamethasone; Drug: methotrexate; Drug: mitoxantrone hydrochloride; Drug: pegaspargase; Drug: temsirolimus; Drug: vincristine sulfate; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Epiretinal Membrane; Macular Edema
Intervention: Drug: Dexamethasone Intravtireal Implant
Sponsors: Barnes Retina Institute; Barnes Retina Institute; Allergan
Recruiting - verified April 2012 - Condition: Postoperative Nausea and Vomiting
Interventions: Drug: Palonosetron; Drug: Ondansetron
Sponsors: Helsinn Healthcare SA; Helsinn Healthcare SA
Recruiting - verified January 2012 - Condition: Myeloma
Interventions: Drug: Hydroxychloroquine; Drug: Rapamycin
Sponsors: Abramson Cancer Center of the University of Pennsylvania; Abramson Cancer Center of the University of Pennsylvania
Recruiting - verified May 2012 - Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide; Drug: Dexamethasone; Drug: Dexamethasone; Drug: Dexamethasone; Biological: Elotuzumab (BMS-901608; HuLuc63); Drug: Lenalidomide; Drug: Lenalidomide
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Abbott Biotherapeutics Corp.
Recruiting - verified October 2011 - Conditions: Postoperative Nausea and Vomiting; Genetic Polymorphisms
Interventions: Drug: Ondansetron; Drug: Lorazepam; Drug: Aprepitant
Sponsors: University of California, San Francisco; University of California, San Francisco; National Cancer Institute (NCI)
Not yet recruiting - verified February 2012 - Conditions: Acute Urinary Tract Infection; Urinary Tract Infection
Interventions: Drug: Placebo; Drug: Dexamethasone
Sponsors: University of Pittsburgh; University of Pittsburgh; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified January 2012 - Condition: Kidney Cancer
Interventions: Drug: Pazopanib; Drug: Temsirolimus; Behavioral: Quality of Life Assessment; Drug: Benadryl
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; GlaxoSmithKline
Not yet recruiting - verified March 2012 - Condition: Multiple Myeloma
Intervention: Drug: MLN9708 + Lenalidomide + Dexamethasone
Sponsors: Millennium Pharmaceuticals, Inc.; Millennium Pharmaceuticals, Inc.
Recruiting - verified May 2012 - Conditions: Light Chain Deposition Disease (LCDD or MIDD); Light Chain and Heavy Chain Deposition Disease (LHCDD or MIDD); Monoclonal Immunoglobulin Deposition Disease (MIDD); Amyloidosis
Intervention: Drug: Bortezomib/Dexamethasone (BD), Followed By Autologous STC & Maintenance Bortezomib/Dexamethasone
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Millennium Pharmaceuticals, Inc.
Recruiting - verified May 2012 - Conditions: Cognitive/Functional Effects; Fatigue; Lymphoma; Neurotoxicity; Therapy-related Toxicity
Interventions: Biological: rituximab; Drug: bortezomib; Drug: dexamethasone; Drug: temsirolimus
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Metastatic ER+ Her2- Breast Cancer; Postmenopausal
Interventions: Drug: Exemestane; Drug: Abiraterone acetate + Prednisone/ Prednisolone + Exemestane; Drug: Abiraterone acetate + Prednisone or Prednisolone
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified May 2012 - Condition: Relapsed Multiple Myeloma
Interventions: Drug: Lenalidomide 15mg; Drug: Lenalidomide 25mg
Sponsors: Boston VA Research Institute, Inc.; Boston VA Research Institute, Inc.; Celgene Corporation; Kansas City Veteran Affairs Medical Center; VA Pittsburgh Healthcare System; VA Greater Los Angeles Healthcare System; Michael Debakey Veterans Affairs Medical Center; Edward Hines Jr. VA Hospital
Recruiting - verified September 2011 - Condition: Chemotherapy-Induced Nausea and Vomiting
Interventions: Drug: Netupitant and Palonosetron; Drug: Aprepitant and Palonosetron
Sponsors: Helsinn Healthcare SA; Helsinn Healthcare SA; Parexel
Recruiting - verified December 2011 - Condition: Multiple Myeloma
Intervention: Drug: Tadalafil, Cialis
Sponsors: Sidney Kimmel Comprehensive Cancer Center; Sidney Kimmel Comprehensive Cancer Center
Recruiting - verified January 2012 - Condition: Myeloma
Interventions: Drug: Arry-520; Drug: Carfilzomib; Drug: Dexamethasone; Drug: Filgrastim
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Array BioPharma; Onyx Therapeutics, Inc.
Recruiting - verified February 2012 - Conditions: Leukemia; Acute Lymphoblastic Leukemia
Interventions: Drug: Inotuzumab Ozogamycin; Drug: Rituximab; Drug: Cyclophosphamide; Drug: Mesna; Drug: Vincristine; Drug: Dexamethasone; Drug: Pegfilgrastim; Drug: Methotrexate; Drug: Ara-C; Drug: Inotuzumab Ozogamycin
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Pfizer
Recruiting - verified April 2012 - Condition: Chemotherapy-induced Nausea and Vomiting
Intervention: Drug: Palonosetron, ondansetron, dexamethasone
Sponsors: Northside Hospital, Inc.; Northside Hospital, Inc.; Blood and Marrow Transplant Group of Georgia
Recruiting - verified March 2012 - Condition: Rheumatoid Arthritis
Interventions: Drug: Prednisolone; Drug: dipyridamole; Drug: Prednisone; Drug: prednisolone-dipyridamole; Other: placebo
Sponsors: Zalicus; Zalicus
Recruiting - verified June 2011 - Condition: Chemotherapy-Induced Nausea and Vomiting
Interventions: Drug: Oral palonosetron; Drug: I.V. palonosetron
Sponsors: Helsinn Healthcare SA; Helsinn Healthcare SA; Parexel
Recruiting - verified December 2011 - Condition: Leukemia
Interventions: Drug: Cyclophosphamide; Drug: Mesna; Drug: Doxorubicin; Drug: Vincristine; Drug: Dexamethasone; Drug: Ofatumumab; Drug: Methotrexate; Drug: Cytarabine
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; GlaxoSmithKline
Recruiting - verified May 2012 - Condition: Chemotherapy Induced Nausea and Vomiting
Interventions: Drug: Aprepitant 125 mg; Drug: Aprepitant 80 mg; Drug: Aprepitant PFS; Drug: Ondansteron; Drug: Placebo for Aprepitant 125 mg; Drug: Placebo for Aprepitant 80 mg; Drug: Placebo for Aprepitant PFS
Sponsors: Merck; Merck
Recruiting - verified May 2012 - Condition: Multiple Myeloma
Interventions: Drug: Amrubicin; Drug: Lenalidomide; Drug: Dexamethasone; Drug: Aspirin
Sponsors: Stanford University; Stanford University; Celgene Corporation
Recruiting - verified October 2011 - Condition: Multiple Myeloma
Interventions: Biological: Anti-CXCR4 (BMS-936564); Biological: Lenalidomide; Biological: Dexamethasone; Biological: Anti-CXCR4 (BMS-936564); Biological: Bortezomib; Biological: Dexamethasone
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified August 2011 - Conditions: Brain and Central Nervous System Tumors; Nausea and Vomiting; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Procedure: acupressure therapy; Procedure: sham intervention
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified October 2011 - Conditions: Cannabis Dependence; Marijuana Dependence
Interventions: Drug: Nabilone; Drug: Placebo
Sponsors: Mclean Hospital; Mclean Hospital; National Institute on Drug Abuse (NIDA)
Recruiting - verified January 2012 - Condition: Chemotherapy-Induced Nausea and Vomiting
Interventions: Drug: Netupitant and Palonosetron; Drug: Palonosetron
Sponsors: Helsinn Healthcare SA; Helsinn Healthcare SA; Parexel
Recruiting - verified December 2011 - Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide; Drug: Dexamethasone; Drug: Dexamethasone; Drug: Dexamethasone; Drug: Dexamethasone; Biological: Elotuzumab (BMS-901608; HuLuc63); Biological: Elotuzumab (BMS-901608; HuLuc63)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Abbott Biotherapeutics Corp.
Recruiting - verified October 2011 - Condition: Myeloma
Intervention: Drug: Simvastatin,Zoledronic Acid,Bortezomib,Bendamustine,Methylprednisolone.
Sponsors: James Graham Brown Cancer Center; Geoffry Herzig, MD
Recruiting - verified April 2012 - Condition: Precursor Cell Lymphoblastic Leukemia-Lymphoma
Intervention: Drug: Filgrastim, Ifosfamide, Etoposide, Dexamethasone, Mesna
Sponsors: Washington University School of Medicine; Washington University School of Medicine
Recruiting - verified October 2011 - Condition: Acute Lymphoblastic Leukemia
Interventions: Drug: Metformin; Drug: Vincristine; Drug: Dexamethasone; Drug: PEG-asparaginase; Drug: Doxorubicin; Drug: Intrathecal chemotherapy
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; H. Lee Moffitt Cancer Center and Research Institute; Pediatric Cancer Foundation
Recruiting - verified April 2012 - Condition: Leukemia
Interventions: Drug: Rituximab; Drug: Imatinib; Drug: Cyclophosphamide; Drug: Doxorubicin; Drug: Mesna; Drug: VSLI; Drug: Solu-Medrol; Drug: Methotrexate; Drug: Ara-C; Drug: G-CSF; Drug: Pegfilgrastim; Drug: Dexamethasone
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Talon Therapeutics, Inc
Not yet recruiting - verified May 2012 - Condition: Acute Kidney Injury
Interventions: Drug: ATG; Drug: Rituximab; Drug: Methylprednisolone; Drug: Diphenhydramine; Drug: Acetaminophen; Drug: Tacrolimus; Drug: Sirolimus; Drug: Hydrocortisone; Drug: Prednisone
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID); Immune Tolerance Network (ITN)
Recruiting - verified August 2011 - Conditions: Sjogren's Syndrome; Xerostomia
Intervention: Drug: Dexamethasone
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Dental and Craniofacial Research (NIDCR)
Recruiting - verified November 2011 - Condition: Acute Lymphoblastic Leukemia
Interventions: Drug: Bortezomib; Drug: Vorinostat; Drug: Dexamethasone; Drug: Methotrexate; Drug: Imatinib mesylate
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota; Millennium Pharmaceuticals, Inc.
Recruiting - verified January 2012 - Condition: Metastatic Colorectal Cancer
Interventions: Drug: panitumumab; Drug: Randomization to No Panitumumab
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Amgen
Recruiting - verified March 2012 - Conditions: Follicular Lymphoma; Diffuse Large B Cell Lymphoma; Mantle Cell Lymphoma; Burkitt's Lymphoma
Intervention: Drug: Imexon
Sponsors: University of Rochester; University of Rochester; University of Arizona
Recruiting - verified June 2011 - Condition: Multiple Myeloma
Intervention: Drug: ACY-1215
Sponsors: Acetylon Pharmaceuticals Incorporated; Acetylon Pharmaceuticals Incorporated; The Leukemia and Lymphoma Society
Recruiting - verified April 2012 - Condition: Prostate CA
Interventions: Drug: Dexamethasone; Procedure: TAP block
Sponsors: Steward St. Elizabeth's Medical Center of Boston, Inc.; Steward St. Elizabeth's Medical Center of Boston, Inc.
Recruiting - verified February 2011 - Condition: Multiple Myeloma
Intervention: Drug: Vorinostat, Lenalidomide, Carfilzomib, Dexamethasone
Sponsors: Hackensack University Medical Center; Hackensack University Medical Center
Recruiting - verified December 2011 - Condition: Community Acquired Respiratory Disease Syndrome
Intervention: Drug: Methylprednisolone
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs
Recruiting - verified April 2012 - A Comparison of 0.5% Loteprednol Etabonate Versus 1% Prednisolone Acetate Following Cataract SurgeryCondition: Intraocular Inflammation
Intervention:
Sponsors: Associated Eye Care, Minnesota; Associated Eye Care, Minnesota; Bausch & Lomb, Inc.
Recruiting - verified June 2011 - Condition: Obsessive-compulsive Disorder
Interventions: Drug: Ondansetron; Drug: Placebo
Sponsors: Transcept Pharmaceuticals; Transcept Pharmaceuticals
Recruiting - verified March 2012 - Conditions: Acute Respiratory Distress Syndrome (ARDS); Acute Lung Injury (ALI)
Interventions: Drug: methylprednisolone; Drug: Normal Saline (0.9%)
Sponsors: University of Tennessee; University of Tennessee
Recruiting - verified July 2011 - Condition: Obesity
Interventions: Other: Placebo; Dietary Supplement: IHBG-10
Sponsors: Avera McKennan Hospital & University Health Center; Avera McKennan Hospital & University Health Center
Not yet recruiting - verified January 2011 - Conditions: Neoplasm Metastases; Hepatic Insufficiency
Interventions: Drug: Hepatic dysfunction group; Drug: Control group
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC; PharmaMar
Recruiting - verified May 2012 - Condition: Neoplasm Metastases
Interventions: Drug: Sequence 1; Drug: Sequence 2; Drug: Sequence 1; Drug: Sequence 2
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified May 2012 - Condition: Acute Migraine
Interventions: Drug: Metoclorpamide; Drug: Ketorolac; Drug: Valproate
Sponsors: Montefiore Medical Center; Montefiore Medical Center
Recruiting - verified April 2012 - Condition: Leukemia
Interventions: Biological: alemtuzumab; Drug: cyclophosphamide; Drug: cytarabine; Drug: dasatinib; Drug: daunorubicin hydrochloride; Drug: dexamethasone; Drug: etoposide phosphate; Drug: fludarabine phosphate; Drug: leucovorin calcium; Drug: melphalan; Drug: mercaptopurine; Drug: methotrexate; Drug: vincristine sulfate; Genetic: polymerase chain reaction; Other: laboratory biomarker analysis; Other: pharmacological study; Procedure: allogeneic hematopoietic stem cell transplantation; Procedure: autologous hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Conditions: Alcohol Abuse; Alcohol Dependence
Interventions: Drug: ondansetron; Drug: placebo ondansetron; Drug: Ondansetron
Sponsors: Johns Hopkins University; Johns Hopkins University; National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Recruiting - verified February 2012 - Condition: Multiple Myeloma, Plasma Cell Leukemia
Interventions: Drug: ARRY-520, KSP(Eg5) inhibitor; intravenous; Drug: Bortezomib, proteasome inhibitor; intravenous; Drug: Dexamethasone, steroid; oral; Drug: Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous
Sponsors: Array BioPharma; Array BioPharma
Recruiting - verified June 2011 - Conditions: Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Cancer
Interventions: Drug: carboplatin; Drug: carboplatin
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; National Institutes of Health (NIH)
Recruiting - verified November 2011 - Condition: Hepatocellular Carcinoma (HCC)
Interventions: Procedure: Transcatheter arterial chemoembolization; Procedure: Stereotactic Body Radiation Therapy
Sponsors: University of Alabama at Birmingham; University of Alabama at Birmingham
Recruiting - verified July 2011 - Conditions: Asthma; Reactive Airway Disease
Interventions: Drug: Dexamethasone; Drug: Prednisone
Sponsors: Alameda County Medical Center; Alameda County Medical Center
Recruiting - verified January 2012 - Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide; Drug: Dexamethasone; Drug: Dexamethasone (Oral); Drug: Dexamethasone (IV); Biological: Elotuzumab (BMS-901608; HuLuc63)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Abbott Biotherapeutics Corp.
Recruiting - verified May 2012 - Condition: Myeloma
Interventions: Drug: Palifermin; Drug: Dexamethasone; Drug: Gemcitabine; Drug: Busulfan; Drug: Melphalan; Procedure: Stem Cell Transplant
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified March 2012 - Condition: Schizophrenia
Interventions: Drug: RO4917838; Drug: RO4917838; Drug: olanzapine; Drug: placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Female Patients With High Tone Pelvic Floor Dysfunction
Interventions: Drug: Vaginal Diazepam Suppository; Drug: Placebo Suppository
Sponsors: TriHealth Inc.; TriHealth Inc.
Recruiting - verified September 2011 - Conditions: Choroidal Neovascularization; Myopia; Punctate Inner Choroidopathy (PIC); Multifocal Choroiditis; Ocular Histoplasmosis Syndrome; Central Serous Chorioretinopathy (CSC); Angioid Streaks; Trauma, or Hereditary Eye Diseases
Interventions: Drug: Bevacizumab (Avastin; Genentech, Inc.); Drug: Bevacizumab, Dexamethasone, Verteporfin Photodynamic Therapy
Sponsors: Massachusetts Eye and Ear Infirmary; Massachusetts Eye and Ear Infirmary
Recruiting - verified April 2012 - Conditions: Macular Edema; Central Retinal Vein Occlusion
Interventions: Drug: Ozurdex; Drug: Avastin
Sponsors: Long Island Vitreoretinal Consultants; Long Island Vitreoretinal Consultants
Recruiting - verified April 2012 - Condition: Relapsed AL Amyloidosis
Interventions: Drug: Bendamustine; Drug: Dexamethasone
Sponsors: University of Pittsburgh; University of Pittsburgh; Cephalon
Not yet recruiting - verified June 2011 - Condition: Esophageal Cancer
Interventions: Drug: Docetaxel; Drug: 5-FU; Radiation: Radiotherapy; Procedure: Esophagectomy; Drug: Dexamethasone
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2012 - Condition: Multiple Myeloma
Interventions: Drug: VELCADE; Drug: Lenalidomide; Drug: Dexamethasone; Drug: DVT prophylaxis; Drug: Bisphosphonates; Drug: Liposomal doxorubicin; Drug: Dexamethasone
Sponsors: Vanderbilt-Ingram Cancer Center; Vanderbilt-Ingram Cancer Center
Recruiting - verified July 2011 - Condition: Refractory Multiple Myeloma
Interventions: Drug: pomalidomide; Drug: bortezomib; Drug: dexamethasone; Other: laboratory biomarker analysis; Other: gene expression analysis
Sponsors: Mayo Clinic; Mayo Clinic; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Delirium; Impaired Cognition; Long Term Psychologic Disorders
Interventions: Drug: Haloperidol; Drug: Ziprasidone; Drug: Placebo
Sponsors: Vanderbilt University; Vanderbilt University
Recruiting - verified December 2011 - Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide; Drug: Bortezomib; Drug: Dexamethasone; Procedure: Autologous Stem Cell Transplant
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute; Celgene Corporation; Millennium Pharmaceuticals, Inc.; Massachusetts General Hospital; Beth Israel Deaconess Medical Center; Emory University; University of Michigan; Fox Chase Cancer Center; Memorial Sloan-Kettering Cancer Center; Fred Hutchinson Cancer Research Center; Barbara Ann Karmanos Cancer Institute; Duke University; University of California, San Francisco; University of Chicago; M.D. Anderson Cancer Center; UNC Lineberger Comprehensive Cancer Center
Recruiting - verified July 2011 - Condition: Primary Headaches (Includes Migraines, Tension, Cluster Headaches)
Interventions: Drug: Droperidol; Drug: Metoclopramide; Drug: Diphenhydramine
Sponsors: University of Iowa; University of Iowa
Recruiting - verified July 2011 - Conditions: Pseudophakia; Cataract Surgery
Interventions: Drug: Pred Forte; Drug: Lotemax
Sponsors: Innovative Medical; Innovative Medical
Recruiting - verified October 2011 - Condition: Multiple Sclerosis, Primary Progressive
Interventions: Drug: ocrelizumab; Drug: Placebo; Drug: methylprednisolone
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Leukemia
Interventions: Drug: cyclophosphamide; Drug: cytarabine; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: pegaspargase; Drug: thioguanine; Drug: vincristine sulfate
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Relapsed Lymphoma; B Cell Non-Hodgkin Lymphoma; Refractory Lymphoma; High Risk Chronic Lymphocytic Leukemia
Interventions: Drug: Rituximab; Biological: Interleukin-2; Biological: Natural killer cells; Drug: Cyclophosphamide; Drug: Methylprednisolone; Drug: Fludarabine
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota
Recruiting - verified April 2012 - Conditions: Cocaine; Alcohol Dependence
Interventions: Drug: Aprepitant; Drug: Placebo
Sponsors: University of Pennsylvania; University of Pennsylvania; National Institute on Drug Abuse (NIDA)
Recruiting - verified August 2011 - Condition: Subsyndromal Delirium
Interventions: Drug: Haloperidol decanoate; Drug: Placebo
Sponsors: Northeastern University; Northeastern University; National Institute on Aging (NIA)
Recruiting - verified April 2012 - Condition: Solid Tumor
Intervention: Drug: PEGPH20
Sponsors: Halozyme Therapeutics; Halozyme Therapeutics
Recruiting - verified June 2011 - Condition: Anorexia Nervosa
Interventions: Drug: Olanzapine; Drug: Placebo
Sponsors: New York State Psychiatric Institute; New York State Psychiatric Institute; National Institute of Mental Health (NIMH); Weill Medical College of Cornell University; University of Pittsburgh; Johns Hopkins University; University of Toronto
Recruiting - verified April 2012 - Conditions: Keratoconus; Ectasia; Degeneration
Interventions: Drug: Ciprofloxicine or Vigamox or other.; Drug: Nonsteroidal (Acular, Acuvail, Voltaren Xibrom, etc); Drug: Steroid (FML, Pred Forte, Flarex, etc.)
Sponsors: Innovative Medical; Innovative Medical
Recruiting - verified April 2012 - Condition: Refractory Multiple Myeloma
Interventions: Drug: azacitidine; Drug: lenalidomide; Drug: dexamethasone; Other: DNA methylation analysis; Other: gene expression analysis; Other: bone marrow aspiration; Other: immunohistochemistry staining method; Other: reverse transcriptase-polymerase chain reaction; Other: flow cytometry
Sponsors: Case Comprehensive Cancer Center; Case Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified February 2012 - Condition: PCOS
Interventions: Drug: Dexamethasone and recombinant hCG; Drug: dexamethasone, human chorionic gonadotrpoin (hCG)
Sponsors: University of California, San Diego; University of California, San Diego; University of Virginia
Recruiting - verified August 2011 - Condition: Gastroparesis
Interventions: Drug: Aprepitant; Drug: Placebo
Sponsors: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Not yet recruiting - verified October 2011 - Condition: Cervical Radiculopathy
Interventions: Other: Gabapentin and/or Nortriptyline, Physical therapy; Procedure: Epidural Steroid Injections (ESI); Other: Combination treatment
Sponsors: Johns Hopkins University; Johns Hopkins University; Walter Reed Army Medical Center
Recruiting - verified September 2010 - Condition: Schizophrenia
Interventions: Drug: LY2140023; Drug: Olanzapine; Drug: Aripiprazole; Drug: Risperidone; Drug: Quetiapine
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012 - Conditions: Schizophrenia; Schizoaffective Disorder
Interventions: Drug: haloperidol decanoate; Drug: paliperidone palmitate
Sponsors: New York State Psychiatric Institute; New York State Psychiatric Institute; National Institute of Mental Health (NIMH); Duke University; University of North Carolina, Chapel Hill
Recruiting - verified January 2012 - Condition: Inflammation Following Cataract Surgery
Interventions: Drug: Difluprednate 0.05% ophthalmic emulsion; Drug: Prednisolone acetate 1.0% ophthalmic suspension
Sponsors: Alcon Research; Alcon Research
Recruiting - verified November 2011 - Condition: Schizophrenia
Interventions: Drug: paliperidone; Drug: risperidone; Drug: haloperidole; Drug: perphenazine; Drug: aripiprazole; Drug: quetiapine; Drug: paliperidone palmitate; Drug: olanzapine
Sponsors: Janssen Scientific Affairs, LLC; Janssen Scientific Affairs, LLC
Recruiting - verified May 2012 - Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide; Drug: lenalidomide, bortezomib and dexamethasone; Drug: Lenalidomide
Sponsors: National Heart, Lung, and Blood Institute (NHLBI); National Heart, Lung, and Blood Institute (NHLBI); Blood and Marrow Transplant Clinical Trials Network; National Cancer Institute (NCI)
Recruiting - verified March 2012 - Conditions: Adult Nasal Type Extranodal NK/T-cell Lymphoma; Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Cutaneous B-cell Non-Hodgkin Lymphoma; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Intraocular Lymphoma; Nodal Marginal Zone B-cell Lymphoma; Peripheral T-cell Lymphoma; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Grade III Lymphomatoid Granulomatosis; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Adult T-cell Leukemia/Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent Small Lymphocytic Lymphoma; Refractory Multiple Myeloma; Small Intestine Lymphoma; Splenic Marginal Zone Lymphoma; Waldenström Macroglobulinemia
Interventions: Drug: bendamustine hydrochloride; Drug: dexamethasone; Biological: filgrastim; Procedure: leukapheresis; Other: laboratory biomarker analysis; Other: flow cytometry; Drug: etoposide
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer; Breast Cancer
Interventions: Drug: Fludarabine; Drug: Cyclophosphamide; Drug: Cyclosporine; Biological: Natural killer cells; Drug: IL-2; Drug: Methylprednisolone; Drug: Methylprednisolone; Drug: Interleukin-2
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota
Recruiting - verified March 2012 - Condition: Hemophagocytic Lymphohistiocytosis
Interventions: Drug: ATG, rabbit; Drug: Etoposide; Drug: Intrathecal Methotrexate; Drug: hydrocortisone
Sponsors: Children's Hospital Medical Center, Cincinnati; Children's Hospital Medical Center, Cincinnati
Recruiting - verified January 2012 - Conditions: Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome; Adult Acute Lymphoblastic Leukemia in Remission; Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Minimally Differentiated Myeloid Leukemia (M0); Adult Acute Monoblastic Leukemia (M5a); Adult Acute Monocytic Leukemia (M5b); Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Erythroleukemia (M6a); Adult Nasal Type Extranodal NK/T-cell Lymphoma; Adult Pure Erythroid Leukemia (M6b); B-cell Adult Acute Lymphoblastic Leukemia; B-cell Childhood Acute Lymphoblastic Leukemia; Blastic Phase Chronic Myelogenous Leukemia; Burkitt Lymphoma; Childhood Acute Erythroleukemia (M6); Childhood Acute Lymphoblastic Leukemia in Remission; Childhood Acute Megakaryocytic Leukemia (M7); Childhood Acute Minimally Differentiated Myeloid Leukemia (M0); Childhood Acute Monoblastic Leukemia (M5a); Childhood Acute Monocytic Leukemia (M5b); Childhood Acute Myeloid Leukemia in Remission; Childhood Chronic Myelogenous Leukemia; Childhood Diffuse Large Cell Lymphoma; Childhood Immunoblastic Large Cell Lymphoma; Childhood Myelodysplastic Syndromes; Childhood Nasal Type Extranodal NK/T-cell Lymphoma; Chronic Myelomonocytic Leukemia; Chronic Phase Chronic Myelogenous Leukemia; Cutaneous B-cell Non-Hodgkin Lymphoma; de Novo Myelodysplastic Syndromes; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Juvenile Myelomonocytic Leukemia; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Nodal Marginal Zone B-cell Lymphoma; Previously Treated Myelodysplastic Syndromes; Prolymphocytic Leukemia; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute Myeloid Leukemia; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Grade III Lymphomatoid Granulomatosis; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Childhood Acute Lymphoblastic Leukemia; Recurrent Childhood Acute Myeloid Leukemia; Recurrent Childhood Anaplastic Large Cell Lymphoma; Recurrent Childhood Grade III Lymphomatoid Granulomatosis; Recurrent Childhood Large Cell Lymphoma; Recurrent Childhood Lymphoblastic Lymphoma; Recurrent Childhood Small Noncleaved Cell Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent Small Lymphocytic Lymphoma; Refractory Chronic Lymphocytic Leukemia; Relapsing Chronic Myelogenous Leukemia; Secondary Acute Myeloid Leukemia; Secondary Myelodysplastic Syndromes; Secondary Myelofibrosis; Splenic Marginal Zone Lymphoma; Stage I Chronic Lymphocytic Leukemia; Stage II Chronic Lymphocytic Leukemia; Stage III Chronic Lymphocytic Leukemia; Stage IV Chronic Lymphocytic Leukemia; T-cell Adult Acute Lymphoblastic Leukemia; T-cell Childhood Acute Lymphoblastic Leukemia; T-cell Large Granular Lymphocyte Leukemia; Waldenstrom Macroglobulinemia
Interventions: Procedure: double-unit umbilical cord blood transplantation; Other: cytogenetic analysis; Procedure: bone marrow aspiration; Other: fluorescence in situ hybridization; Drug: busulfan; Drug: cyclophosphamide; Drug: anti-thymocyte globulin; Drug: methylprednisolone; Drug: cyclosporine; Drug: mycophenolate mofetil; Other: flow cytometry; Procedure: allogeneic hematopoietic stem cell transplantation
Sponsors: Case Comprehensive Cancer Center; Case Comprehensive Cancer Center
Recruiting - verified January 2012 - Condition: Malignant Pleural Mesothelioma
Interventions: Drug: NGR-hTNF plus Best Investigator Choice (BIC); Drug: Placebo plus Best Investigator Choice (BIC)
Sponsors: MolMed S.p.A.; MolMed S.p.A.
Recruiting - verified December 2011 - Condition: Posttraumatic Stress Disorder
Interventions: Drug: Dexamethasone; Drug: Placebo (sugar pill)
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs
Recruiting - verified January 2012 - Condition: Waldenstrom's Macroglobulinemia
Interventions: Drug: pomalidomide; Drug: dexamethasone; Drug: rituximab
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute; Celgene Corporation
Recruiting - verified June 2011 - Conditions: Post Operative Nausea and Vomiting; Rescue Emetic Therapy
Interventions: Drug: Metaclopramide; Drug: Ondansetron; Drug: diphenhydramine; Drug: Saline
Sponsors: Children's Hospital of Pittsburgh; Children's Hospital of Pittsburgh
Recruiting - verified September 2009 - Condition: Gastroparesis
Intervention: Drug: Domperidone
Sponsors: Allegiance Health; Allegiance Health
Recruiting - verified June 2011 - Condition: Non-infectious, Non-necrotizing Anterior Scleritis
Interventions: Drug: Dexamethasone Phosphate Ophthalmic Solution (EGP-437); Drug: Dexamethasone phosphate ophthalmic solution
Sponsors: University of Pennsylvania; John Kempen; FDA Office of Orphan Products Development; Eyegate Pharmaceuticals, Inc.
Recruiting - verified May 2012 - Conditions: Multiple Myeloma; Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma
Interventions: Drug: carfilzomib; Drug: cyclophosphamide; Drug: thalidomide; Drug: dexamethasone
Sponsors: Mayo Clinic; Mayo Clinic
Recruiting - verified April 2012 - Condition: Lymphoma, B-Cell
Interventions: Drug: inotuzumab ozogamicin+rituximab +cyclophosphamide+vincristine+prednisone; Drug: inotuzumab ozogamicin+rituximab+gemcitabine+cisplatinum+dexamethasone
Sponsors: Pfizer; Pfizer; UCB, Inc.
Recruiting - verified May 2012 - Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide; Drug: Prednisone; Drug: Dexamethasone
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; H. Lee Moffitt Cancer Center and Research Institute; Celgene Corporation
Recruiting - verified February 2012 - Condition: Refractory Multiple Myeloma
Interventions: Drug: bendamustine hydrochloride; Drug: lenalidomide; Drug: dexamethasone
Sponsors: Mayo Clinic; Mayo Clinic
Recruiting - verified April 2012 - Condition: Multiple Sclerosis
Interventions: Drug: ACTH; Drug: Methylprednisolone
Sponsors: University of Southern California; University of Southern California; Questcor Pharmaceuticals, Inc.
Recruiting - verified July 2011 - Condition: Prostate Cancer
Interventions: Drug: Ketoconazole, hydrocortisone; Drug: Ketoconazole, dexamethasone
Sponsors: University of California, San Francisco; University of California, San Francisco
Recruiting - verified March 2012 - Conditions: Breakthrough Nausea and Vomiting; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: fosaprepitant dimeglumine; Drug: systemic chemotherapy; Other: survey administration; Procedure: quality-of-life assessment
Sponsors: OHSU Knight Cancer Institute; OHSU Knight Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Acute Otitis Media With Tympanostomy Tubes.; Healthy Subjects With Tympanostomy Tubes.
Intervention: Drug: Ciprodex (0.3% ciprofloxacin/0.1% dexamethasone)
Sponsors: Alcon Research; Alcon Research
Recruiting - verified May 2012 - Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple MyelomaCondition: Multiple Myeloma
Interventions: Drug: Panobinostat; Drug: Bortezomib
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Breast Cancer
Interventions: Biological: HER2Bi-armed activated T cells; Drug: Cyclophosphamide; Other: Laboratory biomarker analysis
Sponsors: Barbara Ann Karmanos Cancer Institute; Barbara Ann Karmanos Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified November 2011 - Condition: Headache
Interventions: Drug: Metoclopramide; Drug: Ketorolac
Sponsors: Montefiore Medical Center; Montefiore Medical Center
Recruiting - verified April 2012 - Condition: Amyloidosis
Intervention: Drug: Bortezomib (Velcade) and Dexamethasone
Sponsors: Boston Medical Center; Boston Medical Center; Millennium Pharmaceuticals, Inc.
Recruiting - verified June 2011 - Condition: Leukemia
Interventions: Drug: cyclophosphamide; Drug: cytarabine; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: imatinib mesylate; Drug: methotrexate; Drug: methylprednisolone; Drug: pegaspargase; Drug: vincristine sulfate; Other: pharmacological study
Sponsors: OHSU Knight Cancer Institute; OHSU Knight Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified March 2011 - Conditions: Keratoconus; Ectasia; Degeneration
Interventions: Drug: Ciprofloxicine or Vigamox or other.; Drug: Nonsteroidal (Acular, Voltaren Xibrom, etc); Drug: Steroid (FML, Pred Forte, Flarex, etc.)
Sponsors: Innovative Medical; Innovative Medical
Recruiting - verified February 2012 - Condition: Multiple Myeloma
Interventions: Drug: Perifosine; Drug: Perifosine Placebo; Drug: Bortezomib; Drug: Dexamethasone
Sponsors: AEterna Zentaris; AEterna Zentaris; Dana-Farber Cancer Institute
Recruiting - verified February 2012 - Condition: Multiple Myeloma
Intervention: Drug: IMGN901
Sponsors: ImmunoGen, Inc.; ImmunoGen, Inc.
Recruiting - verified October 2011 - Condition: Immune Thrombocytopenic Purpura
Interventions: Drug: Dexamethasone USP Micronized; Drug: Prednisone
Sponsors: National Heart, Lung, and Blood Institute (NHLBI); National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified July 2011 - Condition: Polycystic Ovary Syndrome
Interventions: Radiation: 3-D Ultrasound; Drug: hCG with and without FSH; Drug: Adrenocorticotropin (ACTH) infusion; Drug: Diazoxide and hCG
Sponsors: University of California, San Diego; University of California, San Diego
Recruiting - verified August 2011 - Condition: Glaucoma
Interventions: Drug: Prednisolone 1%; Drug: Diclofenac 0.1%; Drug: Artificial Tears
Sponsors: University of Miami; University of Miami; Bascom Palmer Eye Institute; University of Pittsburgh
Recruiting - verified August 2011 - Conditions: Bipolar I Disorder; Schizophrenia
Interventions: Drug: Olanzapine; Behavioral: Standard behavioral weight intervention; Behavioral: Intense behavioral weight intervention
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012 - Conditions: Leukemia; Acute Lymphocytic Leukemia
Interventions: Drug: Everolimus (RAD001); Drug: Cyclophosphamide; Drug: Vincristine; Drug: Doxorubicin; Drug: Dexamethasone; Drug: Mesna; Drug: Methotrexate; Drug: Ara-C (Cytarabine); Drug: Solu-Medrol; Drug: G-CSF
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Novartis
Recruiting - verified November 2011 - Condition: Hemangioma of Infancy
Interventions: Drug: propranolol; Drug: Prednisolone
Sponsors: Children's Research Institute; Children's Research Institute
Recruiting - verified October 2011 - Conditions: Nausea; Vomiting
Interventions: Drug: aprepitant; Drug: Ondansetron
Sponsors: University of Vermont; University of Vermont; Mayo Clinic; Comprehensive Cancer Center of Wake Forest University
Recruiting - verified March 2012 - Conditions: Hematologic Diseases; Acute Myelogenous Leukemia; Myelodysplastic Syndrome; Chronic Myelogenous Leukemia
Interventions: Drug: Ondansetron; Drug: Aprepitant
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified January 2012 - Condition: Nasopharyngeal Carcinoma
Interventions: Drug: Docetaxel; Drug: Carboplatin; Drug: Dexamethasone; Drug: EBV-specific cytotoxic T lymphocytes
Sponsors: Baylor College of Medicine; Baylor College of Medicine; Texas Children's Hospital; The Methodist Hospital System; Center for Cell and Gene Therapy, Baylor College of Medicine; M.D. Anderson Cancer Center
Recruiting - verified April 2012 - Conditions: Leukemia; Acute Lymphoblastic Leukemia
Intervention: Drug: Dasatinib, Mitoxantrone, Cytarabine
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Bristol-Myers Squibb
Recruiting - verified January 2012 - Conditions: Nausea; Vomiting
Intervention: Drug: fosaprepitant
Sponsors: OHSU Knight Cancer Institute; OHSU Knight Cancer Institute
Recruiting - verified December 2011 - Condition: Multiple Myeloma
Intervention: Drug: Vorinostat, Lenalidomide, Bortezomib, Dexamethasone
Sponsors: Emory University; Emory University; Merck; Celgene Corporation
Recruiting - verified April 2012 - Conditions: Advanced Non-small Cell Lung Cancer; Postmenopausal Women
Interventions: Drug: fulvestrant (Faslodex); Drug: anastrozole (Arimidex); Drug: Bevacizumab (Avastin); Drug: Best standard of care
Sponsors: University of Pittsburgh; University of Pittsburgh
Recruiting - verified January 2012 - Conditions: Graft Versus Host Disease; Recurrent Adult Acute Lymphoblastic Leukemia
Interventions: Drug: prednisone; Drug: methylprednisolone; Other: questionnaire administration
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified February 2012 - Condition: Migraine Headache
Interventions: Drug: bupivicaine/methylprednisolone (Active Injection); Drug: Placebo Injection
Sponsors: Mayo Clinic; Mayo Clinic
Recruiting - verified November 2011 - Condition: Pulmonary Nodule
Interventions: Drug: dexamethasone; Procedure: computed tomography; Radiation: fludeoxyglucose F 18
Sponsors: Barbara Ann Karmanos Cancer Institute; Barbara Ann Karmanos Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified November 2011 - Condition: Leukemia, Lymphocytic, Acute
Interventions: Drug: Methotrexate; Drug: Vincristine; Drug: PEG-l-asparaginase; Drug: Dexamethasone; Drug: Rituximab
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified March 2012 - Conditions: Alcoholism; Alcohol Dependence; Post-Tramatic Stress Disorder; fMRI
Intervention: Drug: Aprepitant
Sponsors: National Institutes of Health Clinical Center (CC); National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Recruiting - verified December 2011 - Condition: Marijuana Abuse
Intervention: Drug: bupropion, diazepam, dronabinol, ramelteon (Investigational Drug)
Sponsors: Johns Hopkins University; Johns Hopkins University; National Institute on Drug Abuse (NIDA)
Recruiting - verified May 2009 - Conditions: Leukemia; Amyloidosis
Interventions: Drug: Lenalidomide; Drug: Melphalan; Drug: Dexamethasone
Sponsors: Stanford University; Stanford University; Celgene Corporation
Recruiting - verified May 2012 - Conditions: Alcohol Abuse; Alcoholism
Interventions: Drug: Ondansetron + BASICS Plus; Drug: Placebo + BASICS Plus
Sponsors: University of Virginia; Bankole Johnson; National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Recruiting - verified February 2012 - Condition: Advanced Cancer, Various, NOS
Interventions: Drug: BMS-833923; Drug: Lenalidomide; Drug: Dexamethasone; Drug: Bortezomib
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Exelixis
Recruiting - verified February 2012 - Conditions: Leukemia, Myeloid, Acute; Leukemia, Lymphoblastic, Acute; Leukemia, Myelocytic, Chronic
Interventions: Other: Allogeneic Lymphocytes; Drug: Fludarabine; Drug: Cyclophosphamide; Drug: Methylprednisolone; Drug: Cyclosporine
Sponsors: National Institutes of Health Clinical Center (CC); National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified November 2011 - Conditions: Non-hodgkins Lymphoma; Hodgkins Lymphoma; Multiple Myeloma
Intervention: Drug: Oncaspar, Doxil, Decadron
Sponsors: Penn State University; Penn State University
Recruiting - verified May 2012 - Condition: Diffuse Large B-cell Lymphoma
Interventions: Drug: RICE; Drug: GaRD Treatment
Sponsors: Loyola University; Loyola University; Genta Incorporated
Recruiting - verified September 2011 - Conditions: Blood Glucose; Lipids
Intervention:
Sponsors: Washington University School of Medicine; Washington University School of Medicine; Pfizer
Recruiting - verified March 2012 - Conditions: Multiple Myeloma; Plasma Cell Leukemia
Interventions: Drug: ARRY-520, KSP(Eg5) inhibitor; intravenous; Drug: Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous; Drug: Dexamethasone, steroid; oral
Sponsors: Array BioPharma; Array BioPharma
Recruiting - verified February 2012 - Condition: Postoperative Nausea and Vomiting
Interventions: Drug: aprepitant; Drug: Comparator: Ondansetron
Sponsors: Merck; Merck
Recruiting - verified May 2012 - Condition: Chemotherapy-Induced Nausea and Vomiting
Interventions: Drug: Experimental: aprepitant; Drug: Experimental: aprepitant; Drug: Experimental: aprepitant; Drug: Experimental: aprepitant; Drug: Experimental: aprepitant; Drug: Experimental: aprepitant; Drug: Experimental: fosaprepitant; Drug: Experimental: fosaprepitant; Drug: Experimental: fosaprepitant; Drug: Comparator: ondansetron
Sponsors: Merck; Merck
Recruiting - verified May 2012 - Measurement of Pituitary Volume and Hormonal Changes in Patients With Post-traumatic Stress DisorderCondition: Posttraumatic Stress Disorder
Interventions: Procedure: MRI of the pituitary; Procedure: DEX/CRH test
Sponsors: Cedars-Sinai Medical Center; Cedars-Sinai Medical Center
Recruiting - verified December 2008 - Condition: Multiple Myeloma
Interventions: Procedure: Stem cell transplant x 1 or x 2; Drug: lenalidomide and dexamethasone
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Tufts Medical Center; Lahey Clinic
Recruiting - verified January 2012 - Condition: Psychotic Disorders
Interventions: Drug: Aripiprazole or Perphenazine; Drug: Metformin; Drug: Olanzapine, quetiapine, risperidone, ziprasidone, aripiprazole, asenapine, iloperidone, or lurasidone
Sponsors: National Institute of Mental Health (NIMH); National Institute of Mental Health (NIMH); Johns Hopkins University; University of Maryland; University of North Carolina, Chapel Hill; The Zucker Hillside Hospital
Recruiting - verified April 2012 - Condition: Leukemia
Interventions: Biological: filgrastim; Biological: graft versus host disease prophylaxis/therapy; Drug: cyclophosphamide; Drug: cytarabine; Drug: dasatinib; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: leucovorin calcium; Drug: methotrexate; Drug: methylprednisolone; Drug: prednisone; Drug: vincristine sulfate; Genetic: cytogenetic analysis; Genetic: polymerase chain reaction; Other: flow cytometry; Procedure: allogeneic hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation; Radiation: total-body irradiation
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Multiple Myeloma; Plasma Cell Neoplasm
Interventions: Drug: Lenalidomide & Dexamethasone; Drug: Lenalidomide & Dexamethasone; Drug: Lenalidomide & Dexamethasone
Sponsors: PrECOG, LLC.; PrECOG, LLC.; Celgene Corporation
Recruiting - verified April 2012 - Condition: Lymphoma
Interventions: Biological: rituximab; Drug: cyclophosphamide; Drug: dexamethasone; Drug: lenalidomide
Sponsors: Mayo Clinic; Mayo Clinic; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide; Drug: Dexamethasone
Sponsors: University of Pittsburgh; University of Pittsburgh
Recruiting - verified May 2012 - Condition: Gastroparesis
Intervention: Drug: Domperidone
Sponsors: Arnold, George, M.D.; Arnold, George, M.D.
Recruiting - verified August 2011 - Condition: Brain Neoplasms
Intervention: Drug: Ferumoxytol
Sponsors: OHSU Knight Cancer Institute; OHSU Knight Cancer Institute; National Cancer Institute (NCI); AMAG Pharmaceuticals, Inc.
Recruiting - verified March 2012 - Condition: Multiple Myeloma
Interventions: Drug: M-VTD-PACE; Drug: TT3-LITE Regimen (L-TT3)
Sponsors: University of Arkansas; University of Arkansas; Millennium Pharmaceuticals, Inc.
Recruiting - verified April 2012 - Conditions: Alcohol Dependence; Anxiety Disorder
Intervention: Drug: disulfiram plus lorazepam
Sponsors: University of New Mexico; University of New Mexico; National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Recruiting - verified January 2012 - Condition: Lymphoma
Interventions: Biological: rituximab; Drug: bortezomib; Drug: cyclophosphamide; Drug: dexamethasone; Other: questionnaire administration; Procedure: quality-of-life assessment
Sponsors: Mayo Clinic; Mayo Clinic; National Cancer Institute (NCI)
Recruiting - verified March 2012 - Condition: Cocaine Dependence
Interventions: Drug: Ondansetron; Drug: Placebo
Sponsors: University of Virginia; University of Virginia; National Institute on Drug Abuse (NIDA)
Recruiting - verified February 2012 - Condition: Oral Chronic Graft-versus-host Disease
Interventions: Drug: Tacrolimus; Drug: Dexamethasone
Sponsors: Dana-Farber Cancer Institute; Brigham and Women's Hospital; Dana-Farber Cancer Institute; Children's Hospital Boston; Beth Israel Deaconess Medical Center; Massachusetts General Hospital
Recruiting - verified February 2011 - Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: dexamethasone; Drug: lenalidomide; Drug: melphalan
Sponsors: Boston Medical Center; Boston Medical Center
Recruiting - verified February 2012 - Conditions: Leukemia; Acute Lymphoblastic Leukemia
Interventions: Drug: Rituximab; Drug: Cyclophosphamide (CTX); Drug: Doxorubicin; Drug: Vincristine; Drug: Dexamethasone; Drug: Methotrexate (MTX); Drug: Cytarabine; Drug: G-CSF; Drug: Mesna; Drug: Pegylated asparaginase; Drug: Pegfilgrastim; Drug: Solumedrol
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified April 2012 - Conditions: Burkitt's Lymphoma; Burkitt'S-like Lymphoma
Interventions: Drug: Rituximab; Drug: Cyclophosphamide; Drug: Doxorubicin; Drug: Vincristine; Drug: Dexamethasone; Drug: G-CSF; Drug: Cytarabine; Drug: Methotrexate
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified December 2011 - Condition: Non-Small Cell Lung Cancer
Interventions: Drug: Paclitaxel; Drug: Gemcitabine; Biological: Avastin
Sponsors: University of Alabama at Birmingham; University of Alabama at Birmingham; Genentech
Recruiting - verified August 2011 - Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: bortezomib; Drug: dexamethasone; Drug: lenalidomide
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified June 2011 - Condition: Leukemia
Interventions: Biological: sargramostim; Drug: busulfan; Drug: cyclophosphamide; Drug: dexamethasone; Drug: etoposide; Procedure: autologous bone marrow transplantation; Procedure: autologous hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation; Radiation: total-body irradiation; Procedure: Bone marrow aspiration and biopsy; Procedure: Apheresis
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota
Recruiting - verified January 2012 - Condition: Fanconi Anemia
Interventions: Biological: anti-thymocyte globulin; Drug: cyclophosphamide; Drug: fludarabine phosphate; Procedure: hematopoietic stem cell transplantation; Drug: methylprednisolone; Drug: filgrastim; Drug: cyclosporine; Drug: Mycophenolate Mofetil
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota
Recruiting - verified December 2011 - Conditions: Neutropenia; Infection
Interventions: Drug: Standard antimicrobial therapy; Biological: Granulocyte transfusions; Drug: G-CFS/dexamethasone; Device: Apheresis machine
Sponsors: National Heart, Lung, and Blood Institute (NHLBI); National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified July 2011 - Condition: Brain Cancer
Intervention: Drug: Palonosetron (Aloxi) and Dexamethasone
Sponsors: Duke University; Duke University; Eisai Inc.; National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified March 2012 - Condition: Status Epilepticus
Intervention: Drug: lorazepam or diazepam
Sponsors: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified February 2012 - Condition: Small Cell Lung Cancer
Interventions: Drug: Cisplatin; Drug: Etoposide; Drug: Placebo; Drug: Cisplatin; Drug: Etoposide; Drug: ZD6474
Sponsors: Hoosier Oncology Group; Hoosier Oncology Group; AstraZeneca
Recruiting - verified March 2012 - Condition: Graft Versus Host Disease
Interventions: Procedure: Photopheresis; Drug: Methylprednisolone
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified March 2012 - Condition: Lymphoma
Interventions: Biological: rituximab; Drug: bortezomib; Drug: carboplatin; Drug: dexamethasone; Drug: etoposide; Drug: ifosfamide; Genetic: polymerase chain reaction; Genetic: western blotting
Sponsors: AIDS Malignancy Clinical Trials Consortium; AIDS Malignancy Clinical Trials Consortium; National Cancer Institute (NCI)
Recruiting - verified December 2011 - Conditions: Autonomic Nervous System Diseases; Orthostatic Hypotension
Interventions: Drug: droxidopa; Drug: placebo; Drug: alpha-methyldopa; Drug: carbidopa; Drug: metyrosine; Drug: levodopa; Drug: atomoxetine; Drug: metoclopramide
Sponsors: Vanderbilt University; Vanderbilt University
Recruiting - verified March 2012 - Condition: Leukemia
Interventions: Drug: cyclophosphamide; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: mercaptopurine; Drug: methotrexate; Drug: pegaspargase; Drug: thioguanine; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI); Eastern Cooperative Oncology Group; Southwest Oncology Group
Recruiting - verified May 2012 - Condition: Leukemia
Interventions: Drug: asparaginase; Drug: cyclophosphamide; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: dexamethasone; Drug: etoposide; Drug: lestaurtinib; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: methylprednisolone; Drug: pegaspargase; Drug: prednisone; Drug: therapeutic hydrocortisone; Drug: vincristine sulfate
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Multiple Myeloma
Interventions: Drug: Bortezomib; Drug: Dexamethasone; Drug: PD 0332991
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: Acute Lymphoblastic Leukemia
Interventions: Drug: Prednisone, Vincristine, Daunorubicin, PEG-L-asparaginase, Erwinia L-asparaginase, Doxorubicin, Cyclophosphamide, Cytarabine, Thioguanine; Drug: Clofarabine, Methotrexate, Mercaptopurine, Dexamethasone, Etoposide, Dasatinib
Sponsors: St. Jude Children's Research Hospital; St. Jude Children's Research Hospital; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Schizophrenia; Schizoaffective Disorder; Bipolar Disorder; Obesity; Metabolic Syndrome
Intervention: Drug: olanzapine and melatonin
Sponsors: Seattle Institute for Biomedical and Clinical Research; Seattle Institute for Biomedical and Clinical Research; Eli Lilly and Company
Recruiting - verified November 2011 - Conditions: Leukemia; Lymphoblastic Lymphoma; Leukemia, Lymphoblastic, Acute
Interventions: Drug: Doxorubicin; Drug: Cyclophosphamide; Drug: Cytarabine; Drug: Dexamethasone; Drug: Methotrexate; Drug: Vincristine; Drug: Nelarabine
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified February 2012 - Conditions: Advanced Cancer; Weight Loss
Intervention: Drug: Olanzapine
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2012 - Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Biological: filgrastim; Drug: dexamethasone; Drug: melphalan; Procedure: autologous hematopoietic stem cell transplantation
Sponsors: Mayo Clinic; Mayo Clinic; National Cancer Institute (NCI)
Recruiting - verified January 2012 - Condition: Acute Lymphoblastic Leukemia
Interventions: Drug: Doxorubicin; Drug: Cytarabine; Drug: Methotrexate; Drug: Vincristine; Drug: Cyclophosphamide; Drug: Methylprednisone; Drug: Hydrocortisone Sodium Succinate; Drug: Dexamethasone; Drug: 6-MP; Drug: PEG-Asparaginase; Drug: Imatinib; Drug: Etoposide; Procedure: Radiation Therapy; Drug: E. coli Asparaginase
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute; Massachusetts General Hospital; Children's Hospital Boston
Recruiting - verified August 2011 - Conditions: Schizophrenia; Schizoaffective Disorder
Interventions: Drug: Olanzapine (Zyprexa); Drug: Typicals
Sponsors: VA Connecticut Healthcare System; VA Connecticut Healthcare System; Clinical Trials Network of Columbia U, Cornell U, and NY Presbyterian Hospital; Eli Lilly and Company
Recruiting - verified March 2012 - Condition: Multiple Sclerosis
Interventions: Drug: megadose oral methylprednisolone; Drug: IV methylprednisolone
Sponsors: Mount Sinai School of Medicine; Fred Lublin; National Multiple Sclerosis Society; Pfizer
Recruiting - verified April 2012 - Conditions: Leukemia; Lymphoma
Interventions: Drug: cyclophosphamide; Drug: cytarabine; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: nelarabine; Drug: pegaspargase; Drug: prednisone; Drug: thioguanine; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Graft vs Host Disease
Intervention: Drug: Dexamethasone 0.01% Solution
Sponsors: National Institutes of Health Clinical Center (CC); National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified July 2011 - Conditions: Acute Lymphoblastic Leukemia; Leukemia
Interventions: Drug: Cyclophosphamide; Drug: Vincristine; Drug: Doxorubicin; Drug: Dexamethasone; Drug: Dasatinib; Drug: Methotrexate; Drug: Ara-C
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Bristol-Myers Squibb
Recruiting - verified November 2011 - Condition: Leukemia
Interventions: Biological: filgrastim; Drug: asparaginase; Drug: cyclophosphamide; Drug: cytarabine; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: etoposide phosphate; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: pegaspargase; Drug: prednisone; Drug: therapeutic hydrocortisone; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2012 - Condition: Fanconi Anemia
Interventions: Drug: Cyclophosphamide; Drug: Fludarabine; Drug: anti-thymocyte globulin (ATG); Procedure: Total Body Irradiation; Procedure: Bone Marrow Transplantation; Drug: Mycophenolate Mofetil; Drug: Methylprednisolone
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota
Recruiting - verified April 2012 - Conditions: Kidney Cancer; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes
Interventions: Biological: anti-thymocyte globulin; Drug: cyclophosphamide; Drug: cyclosporine; Drug: fludarabine phosphate; Drug: mycophenolate mofetil; Procedure: stem cell transplantation; Radiation: total-body irradiation; Drug: methylprednisolone; Drug: allopurinol; Drug: filgrastim
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota
Recruiting - verified April 2012 - Condition: Childhood Langerhans Cell Histiocytosis
Interventions: Drug: leucovorin calcium; Drug: methotrexate; Drug: prednisolone; Drug: vinblastine sulfate
Sponsors: National Cancer Institute (NCI); Histiocyte Society
Recruiting - verified May 2007 - Condition: Fanconi Anemia
Interventions: Biological: anti-thymocyte globulin; Biological: filgrastim; Drug: busulfan; Drug: cyclophosphamide; Drug: fludarabine phosphate; Drug: methylprednisolone; Biological: Hematopoietic stem cell transplantation
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota
Recruiting - verified April 2012 - Conditions: Autonomic Failure; Orthostatic Hypotension
Interventions: Drug: Atomoxetine; Drug: Acarbose; Drug: Pyridostigmine Bromide; Drug: Yohimbine; Drug: Midodrine HCl; Drug: placebo; Drug: Modafinil; Drug: Octreotide; Other: water intake; Drug: Diphenhydramine Hydrochloride; Drug: Ranitidine HCL; Drug: Tranylcypromine; Drug: Ergotamine/ Caffeine; Drug: Celecoxib; Drug: Pseudoephedrine; Drug: Methylphenidate; Drug: Indomethacin; Drug: Ibuprofen; Drug: Oxymetazoline 0.05% nasal solution; Dietary Supplement: Bovril; Drug: Acetazolamide; Drug: Rivastigmine tartrate; Drug: Carbidopa/levodopa; Device: abdominal binder; Device: abdominal binder (sham)
Sponsors: Vanderbilt University; Vanderbilt University
Recruiting - verified May 2012 - Condition: Multiple Myeloma
Interventions: Procedure: Stem Cell Transplant; Drug: Cyclophosphamide + Mesna; Drug: Melphalan; Biological: Granulocyte-colony stimulating factor; Drug: Dexamethasone
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota
Recruiting - verified March 2012 - Conditions: Acute Lymphoblastic Leukemia; Lymphoma, Lymphoblastic
Interventions: Drug: Etoposide, cytarabine, vincristine, dexamethasone; Drug: methotrexate, teniposide, PEG-asparaginase; Drug: mitoxantrone, cyclophosphamide, mercaptopurine, vinblastine; Drug: L-asparaginase, erwinia asparaginase; Procedure: chemotherapy, intrathecal chemotherapy, steroid therapy; Procedure: Hematopoietic Stem Cell Transplant; Procedure: Natural Killer (NK) Cell Transplant
Sponsors: St. Jude Children's Research Hospital; St. Jude Children's Research Hospital
Recruiting - verified March 2012 - Conditions: Childhood Langerhans Cell Histiocytosis; Fanconi Anemia; Leukemia; Lymphoma; Myelodysplastic Syndromes; Neuroblastoma; Sarcoma; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Biological: anti-thymocyte globulin; Drug: busulfan; Drug: cyclophosphamide; Drug: fludarabine phosphate; Drug: melphalan; Drug: methylprednisolone; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Milton S. Hershey Medical Center
Recruiting - verified October 2008 - Condition: Lymphoma
Interventions: Biological: rituximab; Drug: cisplatin; Drug: cytarabine; Drug: dexamethasone; Drug: gemcitabine hydrochloride; Other: clinical observation
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Recruiting - verified May 2012 - Condition: Alcoholism
Interventions: Drug: ondansetron + cognitive behavioral therapy; Drug: topiramate + cognitive behavioral therapy; Drug: Placebo + cognitive behavioral therapy; Drug: ondansetron + topiramate + cognitive behavioral therapy
Sponsors: University of Virginia; Bankole Johnson; National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Recruiting - verified February 2012


